Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId
PublicationView,CA210152,10.1002/mrm.30016,Magn Reson Med,38265182,https://pubmed.ncbi.nlm.nih.gov/38265182,Quantitative MRI reveals heterogeneous impacts of treatment on diseased bone marrow in a mouse model of myelofibrosis,2024,"Bone marrow, MRI, Myelofibrosis, Treatment Response","Tanner H Robison, Winston Lee, Kathryn E Luker, Kristen Pettit, Moshe Talpaz, Thomas L Chenevert, Brian D Ross, Gary D Luker","Purpose: Analyzing bone marrow in the hematologic cancer myelofibrosis requires endpoint histology in mouse models and bone marrow biopsies in patients. These methods hinder the ability to monitor therapy over time. Preclinical studies typically begin treatment before mice develop myelofibrosis, unlike patients who begin therapy only after onset of disease. Using clinically relevant, quantitative (Read more on Pubmed)","Magnetic Resonance Imaging, ",Primary Myelofibrosis        ,Bone Marrow        ,Not Applicable,Open Access,38265182,feaa559f-fbf9-4f74-94f7-1cfe9861dab6,syn52500278
